Nuwellis (NASDAQ:NUWE) Stock Rating Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Nuwellis (NASDAQ:NUWE – Free Report) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Nuwellis in a research report on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Get Our Latest Report on Nuwellis

Nuwellis Trading Down 2.6%

NUWE traded down $0.13 during trading on Friday, hitting $4.90. 22,121 shares of the company traded hands, compared to its average volume of 2,117,643. The company has a market cap of $2.65 million, a PE ratio of -0.00 and a beta of 0.03. The stock’s 50-day simple moving average is $6.03 and its two-hundred day simple moving average is $206.53. Nuwellis has a 1 year low of $2.52 and a 1 year high of $1,556.07.

Nuwellis (NASDAQ:NUWE – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($5.81) EPS for the quarter, topping the consensus estimate of ($122.85) by $117.04. The business had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $2.50 million. Nuwellis had a negative net margin of 150.50% and a negative return on equity of 1,259.16%.

Nuwellis Company Profile

(Get Free Report)

Nuwellis, Inc. is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated. Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs.

Recommended Stories

Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.